Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD22 nanobody
- Development stage
- Unknown
- Lead developer
- ME Therapeutics
- Modality
- Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
CD22 nanobody (In vivo CAR) is an experimental immunotherapy being developed by ME Therapeutics for the treatment of B-cell blood cancers. This approach utilizes a CD22-targeting nanobody as the antigen-binding domain of a chimeric antigen receptor (CAR) that is delivered and expressed in immune cells directly within the patient's body (in vivo). By targeting CD22, a protein highly expressed on the surface of B-cell malignancies, the therapy directs the patient's own immune system to identify and destroy cancerous cells. The program is currently in Phase 1 clinical development.
- Other names
- CD22 nanobody (In vivo CAR)CD22-targeting nanobodyCD-22-targeting nanobodyCD 22-targeting nanobody
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CD22 nanobody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD22 nanobody.